论文部分内容阅读
万古霉素作为青霉素的替换药物用于耐青霉素的金黄色葡萄球菌性感染、耐甲氧西林金葡菌等的革兰阳性菌感染。作为治疗耐甲氧西林金葡菌感染的一线药物,万古霉素曾引发诸多不良反应,包括输液相关性毒性、肾毒性等。从而成为研究最多的抗生素之一。针对多种患者群体的万古霉素药动学研究和商品药物的分析方法的建立,使临床医师可以把万古霉素的血浆浓度精确地控制在一个相对狭窄的范围内,继而可以减小产生肾毒性和耳毒性的风险,同时获得有效的治疗浓度。该报告评估了万古霉素血浆浓度监测的相关科学数据与存在的争论,并基于已有证据给出推荐意见。
Vancomycin as a penicillin replacement drug for penicillin-resistant Staphylococcus aureus infections, methicillin-resistant Staphylococcus aureus and other Gram-positive bacteria. As a first-line drug for the treatment of methicillin-resistant Staphylococcus aureus, vancomycin has caused a number of adverse reactions, including infusion-related toxicity, nephrotoxicity and the like. Thus becoming one of the most studied antibiotics. Vancomycin pharmacokinetics and commercial drug analysis for multiple patient populations allow clinicians to precisely control vancomycin plasma concentrations in a relatively narrow range, which in turn can reduce the risk of developing kidney Toxicity and ototoxicity, while achieving effective therapeutic concentrations. The report assesses the relevant scientific data on the monitoring of vancomycin plasma concentrations and the existing controversies and gives recommendations based on available evidence.